CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Palbociclib and letrozole in advanced breast cancer

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · see citing works

Ribociclib as first-line therapy for HR-positive, advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039 · see citing works

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900 · see citing works

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827 · see citing works

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744 · see citing works

MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy

Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680 · see citing works

Palbociclib in hormone-receptor-positive advanced breast cancer

Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590 · see citing works

CDK4/6 inhibition triggers anti-tumour immunity

Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · see citing works

Treating cancer with selective CDK4/6 inhibitors

O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137 · see citing works

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743 · see citing works

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Dieras, V. C., Patt, D. A., Wildiers, H. P. M. W., Hudis, C. A., O’Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 683 · see citing works

Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators

Senderowicz, A. M. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 494 · see citing works

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Senderowicz, A. M., Headlee, D. J., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K. D., Steinberg, S. M., Figg, W. D., Tompkins, A. C., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2986 · Cited by 404 · see citing works

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M. E., Blum, K. A., Rovin, B. H., Brooker-McEldowney, M., et al. (2006) · Blood · doi:10.1182/blood-2006-05-020735 · Cited by 393 · see citing works

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R. K., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 319 · see citing works

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260 · see citing works

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168 · see citing works

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,735 · see citing works

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update

Tadesse, S., Caldon, C. E., Tilley, W. D., & Wang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 285 · see citing works

Development of dual and selective degraders of cyclin-dependent kinases 4 and 6

Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272 · see citing works

N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2

Wang, H., Xu, B., & Shi, J. (2019) · Gene · doi:10.1016/j.gene.2019.144076 · Cited by 220 · see citing works

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)

Sánchez-Martínez, C., Lallena, M. J., Sanfeliciano, S. G., & de Dios, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126637 · Cited by 200 · see citing works

PROTACs to address the challenges facing small molecule inhibitors

Martín-Acosta, P., & Xiao, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112993 · Cited by 186 · see citing works

Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib

Poratti, M., & Marzaro, G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.064 · Cited by 115 · see citing works

Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures

Cheng, W., Yang, Z., Wang, S., Li, Y., Han, W., Tian, X., & Kan, Q. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.003 · Cited by 111 · see citing works

Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis

Desnoyers, A., Nadler, M. B., Kumar, V., Saleh, R., & Amir, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102086 · Cited by 81 · see citing works

Computational analysis of protein-ligand interaction by targeting a cell cycle restrainer

Singh, R., & Purohit, R. (2023) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2023.107367 · Cited by 73 · see citing works

Synthetic Approaches to the New Drugs Approved During 2017

Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Helal, C. J., & O’Donnell, C. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00196 · Cited by 72 · see citing works

A kinase-independent role for CDK8 in BCR-ABL1+ leukemia

Menzl, I., Zhang, T., Berger‐Becvar, A., Grausenburger, R., Heller, G., Prchal‐Murphy, M., Edlinger, L., Knab, V. M., Uras, I. Z., Grundschober, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12656-x · Cited by 68 · see citing works

CDK8 maintains stemness and tumorigenicity of glioma stem cells by regulating the c-MYC pathway

Fukasawa, K., Kadota, T., Horie, T., Tokumura, K., Terada, R., Kitaguchi, Y., Park, G., Ochiai, S., Iwahashi, S., Okayama, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01745-1 · Cited by 68 · see citing works

CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells

Nilmani, D'costa, M., Bothe, A., Das, S., Kumar, S. U., Ramanathan, G., & Doss, C. G. P. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.008 · Cited by 59 · see citing works

Identification of Breast Malignancy by Marker-Controlled Watershed Transformation and Hybrid Feature Set for Healthcare

Sadad, T., Hussain, A., Munir, A., Habib, M., Khan, S. A., Hussain, S., Yang, S., & Alawairdhi, M. (2020) · Applied Sciences · doi:10.3390/app10061900 · Cited by 57 · see citing works

Amalgamated Microneedle Array Bearing Ribociclib-Loaded Transfersomes Eradicates Breast Cancer via CD44 Targeting

Sharma, M. S., Mittapelly, N., Banala, V. T., Urandur, S., Gautam, S., Marwaha, D., Rai, N., Singh, N., Gupta, A., Mitra, K., et al. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.1c01076 · Cited by 56 · see citing works

An update of new small-molecule anticancer drugs approved from 2015 to 2020

Liang, X., Wu, P., Yang, Q., Xie, Y., He, C., Yin, L., Yin, Z., Yue, G., Zou, Y., Li, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113473 · Cited by 53 · see citing works

CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms

Skowron, M. A., Vermeulen, M., Winkelhausen, A., Becker, T. K., Bremmer, F., Petzsch, P., Schönberger, S., Calaminus, G., Köhrer, K., Albers, P., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0891-x · Cited by 52 · see citing works

Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity

Cheng, C., Yun, F., Ullah, S., & Yuan, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112073 · Cited by 50 · see citing works

2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study

Aboulwafa, O. M., Daabees, H. G., & Badawi, W. A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103798 · Cited by 47 · see citing works

Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer

Goel, B., Tripathi, N., Bhardwaj, N., & Jain, S. K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200516152756 · Cited by 45 · see citing works

Development of PROTAC degrader probe of CDK4/6 based on DCAF16

Pu, C., Liu, Y., Deng, R., Xu, Q., Wang, S., Zhang, H., Luo, D., Ma, X., Tong, Y., Ma, X., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106637 · Cited by 43 · see citing works

CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety

Wekking, D., Lambertini, M., Dessì, M., Denaro, N., Bardanzellu, F., Garrone, O., Scartozzi, M., & Solinas, C. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2024.01.002 · Cited by 42 · see citing works

Promises of natural products as clinical applications for cancer

Deng, R., Zong, G., Wang, X., Yue, B.-J., Cheng, P., Tao, R., Li, X., Wei, Z., & Lu, Y. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189241 · Cited by 40 · see citing works

CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets

Kohlmeyer, J. L., Gordon, D. J., Tanas, M. R., Monga, V., Dodd, R. D., & Quelle, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083018 · Cited by 40 · see citing works

Degradation strategy of cyclin D1 in cancer cells and the potential clinical application

Chen, S., & Li, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949688 · Cited by 35 · see citing works

Deciphering the interaction of puerarin with cancer macromolecules: An in silico investigation

Ojo, O. A., Aruleba, R. T., Adekiya, T. A., Sibuyi, N. R. S., Ojo, A. B., Ajiboye, B. O., Oyinloye, B. E., Adeola, H. A., & Fadaka, A. O. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1819425 · Cited by 33 · see citing works

How selective are clinical CDK4/6 inhibitors?

Hendrychová, D., Jorda, R., & Kryštof, V. (2020) · Medicinal Research Reviews · doi:10.1002/med.21769 · Cited by 35 · see citing works

Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: Past, present and future perspectives

Ha, S., Zhu, J., Xiang, H., & Luo, G. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109192 · Cited by 34 · see citing works

Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines

Badawi, W. A., Samir, M. A., Fathy, H. M., Okda, T. M., Noureldin, M. H., Atwa, G. M. K., & Aboulwafa, O. M. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106610 · Cited by 32 · see citing works

New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells

FARGHALY, A. M., Aboulwafa, O. M., Baghdadi, H. H., Razik, H. A. A. E., Sedra, S. M. Y., & Shamaa, M. M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105208 · Cited by 32 · see citing works

Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations

Shebbo, S., Alateyah, N., Yassin, E., Mahmoud, D. E. S., Tamimi, F., Anweigi, L. M., Elhissi, A. M. A., Abou-Saleh, H., Elrayess, M. A., & Agouni, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1626243 · Cited by 31 · see citing works

Small-molecule PROTACs: Novel Agents for Cancer Therapy

Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 32 · see citing works

Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect

Wang, S., Zhou, D., Xu, Z., Song, J., Qian, X., Lv, X., & Luan, J. (2019) · Current Drug Targets · doi:10.2174/1389450120666190402145325 · Cited by 29 · see citing works

Azaindole derivatives as potential kinase inhibitors and their SARs elucidation

Fang, G., Chen, H., Cheng, Z., Tang, Z., & Wan, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115621 · Cited by 28 · see citing works

Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences

Ye, Y., Huang, Z., Zhang, M., Li, J., Zhang, Y., & Lou, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114183 · Cited by 24 · see citing works

Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons

Ibrahim, S., Khan, M. U., Khurram, I., Rehman, R., Rauf, A., Ahmad, Z., Aljohani, A. S. M., Abdulmonem, W. A., & Quradha, M. M. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70011 · Cited by 23 · see citing works

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors

Li, X., Yang, T., Hu, M., Yang, Y., Tang, M., Deng, D., Liu, K., Fu, S., Tan, Y. L., Wang, H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105669 · Cited by 19 · see citing works

Herbal Ingredients in the Prevention of Breast Cancer: Comprehensive Review of Potential Molecular Targets and Role of Natural Products

Akkol, E. K., Bardakçı, H., Barak, T. H., Aschner, M., Karatoprak, G. Ş., Khan, H. Z., & Hussain, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6044640 · Cited by 19 · see citing works

Multi or Single-Kinase Inhibitors to Counteract Drug Resistance in Cancer: What is New?

Pecoraro, C., Carbone, D., Cascioferro, S., Parrino, B., & Diana, P. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220729152741 · Cited by 17 · see citing works

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer

Qiu, J., Bai, X., Zhang, W., Ma, M., Wang, W., Ye, L., Wang, H., Tian, J., & Yu, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.853993 · Cited by 17 · see citing works

Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics

Kommineni, N., Paul, D., Saka, R., Khan, W., & Satheeshkumar, N. (2022) · Nanotheranostics · doi:10.7150/ntno.76370 · Cited by 16 · see citing works

A comprehensive review on nanocarriers as a targeted delivery system for the treatment of breast cancer

Fatima, A., Naseem, N., Haider, M. F., Rahman, M. A., Mall, J., Saifi, M. S., & Akhtar, J. (2024) · Intelligent Pharmacy · doi:10.1016/j.ipha.2024.04.001 · Cited by 15 · see citing works

The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature

Garufi, G., Carbognin, L., Orlandi, A., Palazzo, A., Tortora, G., & Bria, E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651723 · Cited by 15 · see citing works

Discovery of 5,7-Dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors

Sokolsky, A., Winterton, S., Kennedy, K., Drake, K., Stump, K., Huo, L., Lo, Y. Y. C., Ye, M., Covington, M. B., Diamond, S., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00408 · Cited by 14 · see citing works

DNA hypomethylation activates Cdk4/6 and Atr to induce DNA replication and cell cycle arrest to constrain liver outgrowth in zebrafish

Madakashira, B. P., Magnani, E., Ranjan, S., & Sadler, K. C. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae031 · Cited by 13 · see citing works

Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6

Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie · doi:10.1002/ange.201901336 · Cited by 14 · see citing works

Combination therapies for MPNSTs targeting RABL6A-RB1 signaling

Kohlmeyer, J. L., Gordon, D. J., Tanas, M. R., Dodd, R. D., Monga, V., Darbro, B. W., & Quelle, D. E. (2021) · Oncotarget · doi:10.18632/oncotarget.27862 · Cited by 12 · see citing works

Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

Occhipinti, G., Romagnoli, E., Santoni, M., Cimadamore, A., Sorgentoni, G., Cecati, M., Giulietti, M., Battelli, N., Maccioni, A., Storti, N., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00349 · Cited by 11 · see citing works

Structure-Guided Discovery of Novel N4-(Substituted Thiazol-2-yl)-N2-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability

Zhang, B., Li, Y., Lin, Y., Wang, T., Chen, L., Cai, J., Ji, T., Diao, P.-C., Ma, Y., Zhang, Y.-T. Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02441 · Cited by 10 · see citing works

New functionalized 6‐thienylpyrimidine‐5‐carbonitriles as antiproliferative agents against human breast cancer cells

Aboulwafa, O. M., Daabees, H. G., Hammad, A., & Badawi, W. A. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202100177 · Cited by 10 · see citing works

Synthesis and Biological Evaluation of 2-Substituted Benzyl-/Phenylethylamino-4-amino-5-aroylthiazoles as Apoptosis-Inducing Anticancer Agents

Oliva, P., Onnis, V., Balboni, E., Hamel, E., Estévez-Sarmiento, F., Quintana, J., Estévez, F., Brancale, A., Ferla, S., Manfredini, S., et al. (2020) · Molecules · doi:10.3390/molecules25092177 · Cited by 8 · see citing works

Insights into the selectivity of a brain-penetrant CDK4/6 vs CDK1/2 inhibitor for glioblastoma used in multiple replica molecular dynamics simulations

Sun, J., Liang, S., Liu, X., Zhang, S., Li, M., Zhang, Q., & Chen, J. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2294175 · Cited by 8 · see citing works

Multi-Kinase Inhibition by New Quinazoline–Isatin Hybrids: Design, Synthesis, Biological Evaluation and Mechanistic Studies

Alanazi, M. M., & Al-Wabli, R. I. (2025) · Pharmaceuticals · doi:10.3390/ph18101546 · Cited by 6 · see citing works

Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country

Abdel‐Razeq, H., Sharaf, B., Khater, S., Baidoun, H., Hani, H. B., Taqash, A., Khatib, O. E., Edaily, S., Abunasser, M., Tamimi, F., et al. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s479153 · Cited by 7 · see citing works

First-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report

Pangarsa, E. A., Astutı, P., Rizky, D., Tandarto, K., Setiawan, B., Winarno, A. A., Santosa, D., & Suharti, C. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04922-4 · Cited by 4 · see citing works

Performance of protein-ligand docking with CDK4/6 inhibitors: a case study

Song, L., Ning, S., Hou, J., & Zhao, Y. (2020) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021025 · Cited by 4 · see citing works

Novel tacrine derivatives as potential CDK9 inhibitors with low cholinesterase inhibitory properties: design, synthesis, and biological evaluation

Liu, W., Huang, Y., Wu, L., Liu, W., Jiang, X., Xu, Z., & Zhao, Q. (2022) · New Journal of Chemistry · doi:10.1039/d2nj03667c · Cited by 4 · see citing works

Real-World Clinical Experience of First-Line Ribociclib Combined with an Aromatase Inhibitor in Metastatic Breast Cancer

Cvetanović, A. S., Jankovic, K. B., Stojković, A. S., Živković, N., Kostić, M. S., & POPOVIC, L. S. (2026) · Cancers · doi:10.3390/cancers18020242 · Cited by 3 · see citing works

QSAR, Molecular Docking & ADMET Studies of Pyrrolo[2,3-d] Pyrimidine Derivatives as CDK4 Inhibitors for the Treatment of Cancer

Patil, S. M., Patil, V. A., Asgonkar, K., Randive, V., & Mahadik, I. (2023) · Current Indian Science · doi:10.2174/012210299x258569231006094309 · Cited by 3 · see citing works

Advanced drug delivery systems in breast cancer

Singh, S., Singh, P., Mishra, N., Maurya, P., Singh, N., Nisha, R., & Saraf, S. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85503-7.00028-6 · Cited by 4 · see citing works

Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma

Shohdy, K. S., Vlachostergios, P. J., Abdelmalek, R., & Faltas, B. M. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1559828 · Cited by 3 · see citing works

Design and Synthesis of Novel Quinazolinone-Based Oxobutanenitrile Derivatives as Antiproliferative Agents Targeting Human Breast Cancer

Ezz-ElDien, E. S., Aboulwafa, O. M., & Daabees, H. G. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666211214104144 · Cited by 2 · see citing works

Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment

Li, L., & Zhang, Q. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266253686230921054429 · Cited by 2 · see citing works

Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials

Yeh, C., Zhou, M., Bapodra, N., Hershman, D. L., Espinal, E., Morán, M., Rivero, M., Fojo, T., & Bates, S. E. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07131-7 · Cited by 3 · see citing works

From Chiral Separation to Asymmetric Synthesis: Route Scouting and Early Process Development of a Chiral Tetrahydrofuran–Pyrazolamine Intermediate of CDK2 Inhibitor RLY-2139

Bag, S., Lescarbeau, A., Che, A. Q., Karnati, V., Fei, Z., Wang, L., Zhang, D., Liu, J., Jiang, F., Wang, H., et al. (2026) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00354 · Cited by 1 · see citing works

Process Development and Scale-Up of RLY-2139: A Selective CDK2 Inhibitor Targeting ER+/HER2– Breast Cancer

Bag, S., Che, A. Q., Lescarbeau, A., Jones, D., Karnati, V., He, J., Taylor, A. M., Heap, C., Briggs, T., Liang, J. C., et al. (2026) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00342 · Cited by 1 · see citing works

Ribociclib-loaded folic acid conjugated chitosan-polycaprolactone hybrid nanoparticles for the management of glioblastoma

Rajana, N., Ravula, S., Quadros, M., Mokashi, M., Islam, M. A., Mehta, D., Alkyam, M., Mehra, N. K., Perron, J. C., Kumar, D. S., et al. (2026) · Biomaterials Advances · doi:10.1016/j.bioadv.2026.214921 · Cited by 1 · see citing works

Enhancing the Solubility, Oral Bioavailability, and Antitumor Effects of Ribociclib through Multicomponent Salt Formation with NSAIDs

Chen, Z., Feng, Y., Wang, C., Han, X., Song, Y., Yao, X., Zhang, G., Wei, R., & Zhuang, T. (2026) · Crystal Growth & Design · doi:10.1021/acs.cgd.6c00153 · Cited by 1 · see citing works

Complete response in metastatic breast cancer with visceral crisis using a combination of cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor: A case report from the eastern region of India

Ahmed, S. S., Majumdar, S. K. D., Dhar, S. S., Mahapatra, B. R., Muraleedharan, A. K., Barik, S. K., & Parida, D. K. (2022) · Indian Journal of Case Reports · doi:10.32677/ijcr.v8i9.3590 · Cited by 1 · see citing works

Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription

Maillard, M., Louveau, B., Vilquin, P., Goldwirt, L., Thomas, F., & Mourah, S. (2021) · Therapies · doi:10.1016/j.therap.2021.11.003 · Cited by 1 · see citing works

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells

Schneeweiss‐Gleixner, M., Filik, Y., Stefanzl, G., Berger, D., Sadovnik, I., Bauer, K., Smiljkovic, D., Eisenwort, G., Witzeneder, N., Greiner, G., et al. (2022) · Cancers · doi:10.3390/cancers14133070

Computational insights into Croton species as sources of CDK4/6 inhibitors for cancer therapy

Obende, S. O., Ochieng, C. O., Shikanga, E. A., Ndarawit, W. K., & Kimani, N. M. (2025) · Scientific African · doi:10.1016/j.sciaf.2025.e03174

Novel active site -targeted fluorescent probes for real-time monitoring of CDK4/6 in tumor cells and tissues

Gao, Y., Qi, S., Dong, G., Cheng, M., Liu, W., Chen, H., Wang, M., Qin, L., Wang, X., Zhang, X., et al. (2026) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2026.127609

A novel green MXene-supported MIP-based platform for the ultrasensitive and selective determination of abemaciclib

Dogan, Z. M., Piskin, E., Türkoğlu, E. A., Çetinkaya, A., Zor, E., Akbayrak, S., Unal, M. A., Atıcı, E. B., & Özkan, S. A. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.119531

BindingDB Entry 50017954: PROTACs to address the challenges facing small molecule inhibitors.

BindingDB (2023) · UC San Diego · doi:10.7270/q2p55sm1

BindingDB Entry 50007709: Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.

BindingDB (2021) · UC San Diego · doi:10.7270/q26q21j2

BindingDB Entry 50007747: Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.

BindingDB (2021) · UC San Diego · doi:10.7270/q27m0c84

BindingDB Entry 50022402: Azaindole derivatives as potential kinase inhibitors and their SARs elucidation.

BindingDB (2025) · UC San Diego · doi:10.7270/q2pr81q8

BindingDB Entry 50011796: Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.

BindingDB (2022) · UC San Diego · doi:10.7270/q21v5jkp

BindingDB Entry 50010555: Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.

BindingDB (2021) · UC San Diego · doi:10.7270/q2c53qdz

BindingDB Entry 50007904: Synthetic Approaches to the New Drugs Approved During 2017.

BindingDB (2021) · UC San Diego · doi:10.7270/q2sx6hk5

BindingDB Entry 50023057: Structure-Guided Discovery of Novel N4-(Substituted Thiazol-2-yl)-N2-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability.

BindingDB (2026) · UC San Diego · doi:10.7270/q2zw1rs2

BindingDB Entry 50009433: Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).

BindingDB (2021) · UC San Diego · doi:10.7270/q23f4t3t

BindingDB Entry 50016582: Discovery of 5,7-Dihydro-6

BindingDB (2023) · UC San Diego · doi:10.7270/q29c72fh

Palbociclib, ribociclib, and abemaciclib: potent and selective CDK4/6 inhibitors for the treatment of breast cancer

Yuan, K., Chen, W., Wang, X., & Yang, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00022-4

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

Braal, C. L., Jongbloed, E. M., Wilting, S. M., Mathijssen, R. H. J., Koolen, S. L. W., & Jager, A. (2020) · Drugs · doi:10.1007/s40265-020-01461-2 · Cited by 451 · see citing works

CDK4/6 inhibition in early and metastatic breast cancer: A review

de Groot, A. F., Kuijpers, C. C. H. J., & Kroep, J. R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.003 · Cited by 60 · see citing works

Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib

Kwapisz, D. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4385-3 · Cited by 207 · see citing works

Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data

Vidula, N., & Rugo, H. S. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.07.005 · Cited by 85 · see citing works